Skip to content
value.today
Aethlon Medical, Inc. logo

Aethlon Medical, Inc.

AEMD
$9 Mmarket cap on Oct 30, 2026+47.8% since Jan 2024
Compare
World rank
#26,127
Revenue
—
For year ending March-2026
Net income
$-7 M
SEC filing
Employees
9
As of June 8, 2026
SEC filing

Aethlon Medical, Inc. in brief

Aethlon Medical, Inc. is a listed company in the Medical Devices industry, based in San Diego, California, USA. It was founded in 1999. Its market value was $9 M on 30 October 2026, which makes it the 26,127th largest listed company in the world and the 4,326th largest in the USA on this site. It employs about 9 people and James B. Frakes is its chief executive. Its shares trade under the symbol AEMD (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Aethlon Medical, Inc.

We are a medical therapeutic company focused on developing the Hemopurifier® (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases.

From the company's annual report filed with the US SEC: read the report

Aethlon Medical, Inc. timeline

4 events, 1997–2020
  1. 1997
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 1999
  4. 🏁
    Founded
  5. 2000
  6. ✎
    Renamed Aethlon Medical Inc
    Formerly Bishop Equities Inc.
  7. 2020
  8. 💰
    Record revenue of $1 million
    FY2020, the highest of the 5 years on record.

Events of Aethlon Medical, Inc. from SEC EDGAR, Wikidata and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$8 M$16 M$24 M$32 M2020202120222023202420252026

World rank over time

▲ up 1,579 places since 2020
2020-01-01: #27718#27,71820202021-01-01: #22207#22,20720212022-01-07: #28761#28,76120222022-12-25: #32420#32,42020222023-07-30: #31916#31,91620232024-01-05: #32146#32,14620242026-03-08: #13544#13,54420262026-08-01: #24081#24,08120262026-10-14: #26144#26,14420262026-10-30: #26139#26,1392026

Rank in USA: #4,845 (Jan 2020) · #4,274 (Jan 2021) · #5,210 (Jan 2022) · #5,721 (Dec 2022) · #5,458 (Jul 2023) · #4,604 (Jan 2024) · #2,486 (Mar 2026) · #4,172 (Aug 2026) · #4,275 (Oct 2026) · #4,329 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.8×
Free cash flow yield
-78.9%
Net margin
—
Operating margin
—
Return on equity
-146.2%
Liabilities / assets
22.9%
Revenue growth
+96.6%
R&D / revenue
480.7%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Mar 2019: revenue $0M, net income $-6M$0MFY19Fiscal year ending Mar 2020: revenue $1M, net income $-6M$1MFY20Fiscal year ending Mar 2021: revenue $1M, net income $-8M$1MFY21Fiscal year ending Mar 2022: revenue $0M, net income $-10M$0MFY22Fiscal year ending Mar 2023: revenue $1M, net income $-12M$1MFY23Fiscal year ending Mar 2024: revenue —, net income $-12M—FY24Fiscal year ending Mar 2025: revenue —, net income $-13M—FY25Fiscal year ending Mar 2026: revenue —, net income $-7M—FY26
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Mar 2026——$-7M$-7M—
Mar 2025——$-9M$-13M—
Mar 2024——$-13M$-12M—
Mar 2023$1M+96.6%$-12M$-12M-2110.5%
Mar 2022$0M-56.1%$-10M$-10M-3593.1%
Mar 2021$1M+1.5%$-8M$-8M-1195.5%
Mar 2020$1M+182.6%$-6M$-6M-980.0%
Mar 2019$0M—$-6M$-6M-2691.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Mar 2026$-7M$0M$-7M$-10.61—
Mar 2025$-8M$0M$-8M$-85.77—
Mar 2024$-10M$0M$-10M$-38.87—
Mar 2023$-11M$1M$-11M$-5.86—
Mar 2022$-10M$0M$-10M$-0.71—
Mar 2021$-7M$0M$-7M$-0.65—
Mar 2020$-5M$0M$-5M$-1.87—
Mar 2019$-4M$0M$-4M$-5.13—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024: revenue —, net income $-2M—Dec ’24Three months to Mar 2025 (from the annual report): revenue —, net income $-6M—Mar ’25Three months to Jun 2025: revenue —, net income $-2M—Jun ’25Three months to Sep 2025: revenue —, net income $-1M—Sep ’25Three months to Dec 2025: revenue —, net income $-2M—Dec ’25Three months to Mar 2026 (from the annual report): revenue —, net income $-2M—Mar ’26Three months to Jun 2026: revenue —, net income $-2M—Jun ’26Three months to Sep 2026: revenue —, net income $-3M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Aethlon Medical, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-7 M
Net income
$-7 M

For year ending March-2026 · source: SEC filing

Balance sheet

Total assets
$6 M
Total liabilities
$1 M
Total equity
$5 M

As of March-2026

Top 17 institutional investors in Aethlon Medical, Inc.#

As of Sep 30, 2026
17 institutions held 515,505 shares (about 32.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 31.1%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 17 largest institutional investors in Aethlon Medical, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Stempoint Capital LP213,685New13.29%$1 MNov 16, 2026
2Birchview Capital, LP62,837New3.91%$0 MNov 13, 2026
3Shay Capital LLC62,249New3.87%$0 MNov 16, 2026
4Diadema Partners LP50,000New3.11%$0 MNov 16, 2026
5Schonfeld Strategic Advisors LLC25,769New1.60%$0 MNov 16, 2026
6HRT Financial LP21,643New1.35%$0 MNov 13, 2026
7Jane Street Group, LLC21,534New1.34%$0 MNov 12, 2026
8StoneX Group Inc.14,861New0.92%$0 MNov 3, 2026
9FNY Investment Advisers, LLC14,500New0.90%$0 MOct 16, 2026
10Persistent Asset Partners Ltd12,700New0.79%$0 MNov 13, 2026
11Level Four Advisory Services, LLC10,000New0.62%$0 MNov 6, 2026
12Tower Research Capital LLC (TRC)2,620New0.16%$0 MNov 16, 2026
13UBS Group AG2,605New0.16%$0 MNov 10, 2026
14Morgan Stanley494New0.03%$0 MNov 13, 2026
15Jones Financial Companies Lllp3New0.00%$0 MNov 13, 2026
16BlackRock, Inc.3New0.00%$0 MNov 13, 2026
17Group One Trading LLC2New0.00%$0 MNov 10, 2026

Mutual funds holding Aethlon Medical, Inc.#

2 funds hold shares worth $0 M (about 1.2% of the company). Since their previous reports 2 added shares and 0 sold, buying $0 M net.
Mutual funds holding Aethlon Medical, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC18,891$0 M1.2%<0.01%+185%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC1,077$0 M0.07%<0.01%+347%May 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of May 31, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Aethlon Medical, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
12
since
Aethlon Medical, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Steven P. LarosaChief Medical OfficerGrant or award+42,000——42,057Form 4
filed James B. FrakesCFO/CEO, DirectorGrant or award+42,000——42,063Form 4
filed Nicolas GikakisDirectorShares withheld for tax-436$6.520$3 K3,784Form 4
filed Chetan ShahDirectorShares withheld for tax-436$6.520$3 K3,787Form 4
filed Edward G. BroennimanDirectorShares withheld for tax-218$6.520$1 K4,313Form 4
filed Chetan ShahDirectorShares withheld for tax-2,182$0.820$2 K20,840Form 4
filed Nicolas GikakisDirectorShares withheld for tax-2,182$0.820$2 K20,663Form 4
filed Edward G. BroennimanDirectorShares withheld for tax-1,091$0.820$89522,363Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Aethlon Medical, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
43,186
13.8% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-08-03 23:50 UTC, code T3, resumed 13:00 UTC
  • 2025-10-17 23:50 UTC, code T3, resumed 13:00 UTC
  • 2025-06-06 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 2,583 shares at $5.52
  • : 8,535 shares at $5.55
  • : 3,834 shares at $5.07
  • : 26,311 shares at $5.15
  • : 18,992 shares at $5.05

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Aethlon Medical, Inc. scorecard#

Passes 3 of the 13 checks that could be worked out: strongest in financial health (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.8×Price to book 1.8× against Medical Devices's median of 2.5×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-78.9%Free cash flow is -78.9% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-10.61 vs -85.77Diluted EPS -10.61 in fiscal 2025 against -85.77 the year before (report's currency).
    • ✓Net income higher than five years earlier-$7 M-$7 M in fiscal 2025 against -$8 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$7 MNet income -$7 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-142.9%-142.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities3.8×Current ratio 3.84 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-729.0×Operating income -729.0 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year332.1%Diluted shares up 332.1% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Aethlon Medical, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Aethlon Medical, Inc.: statements by fiscal year
PeriodTrendFY 2025to Mar 31, 2026FY 2024to Mar 31, 2025FY 2023to Mar 31, 2024FY 2022to Mar 31, 2023FY 2021to Mar 31, 2022FY 2020to Mar 31, 2021FY 2019to Mar 31, 2020FY 2018to Mar 31, 2019FY 2017to Mar 31, 2018FY 2016to Mar 31, 2017
Income statement
Revenue——00.60.30.70.70.20.10.4
Research and development1.92.22.52.72.32.10.90.90.60.7
General and administrative2.73.23.94.53.52.5r1.51.00.80.8
Operating expenses7.39.31312118.6r6.66.25.06.5
Operating income−7.3−9.3−13−12−10−7.9r−5.9−6.0−4.8−6.1
Interest and finance income0.20.3————————
Interest expense and finance costs0.00.0————————
Other non-operating income (expense)0.1−4.0———−0.0−0.5−0.2——
Income before tax−7.2−13————————
Income tax0000000000
Net income including minority interests———−12−10−7.9−6.4−6.2−5.7−7.3
Minority interests' share of net income———0−0.0−0.0−0.0−0.0−0.0−0.0
Net income attributable to shareholders−7.2−13−12−12−10−7.9−6.4−6.2−5.7−7.3
Earnings per share, basic-10.61-85.77r-38.87r-5.86r-0.71-0.65-1.87-5.13r-0.10r-0.94
Earnings per share, diluted-10.61-85.77r-38.87r-5.86r-0.71-0.65-1.87-5.13r-0.10r-0.94
Shares, weighted average (basic)0.70.2r0.3r2.1r15—————
Shares, weighted average (diluted)0.70.2r0.3r2.1r15123.41.2r127.8
Balance sheet
Cash and cash equivalents5.05.55.415179.99.6r3.87.01.6
Receivables———00.10.10.200.10
Other current assets0.30.40.50.61.00.30.20.20.20.0
Current assets5.65.96.2151810104.07.21.6
Property, plant and equipment0.40.71.01.10.40.20.10.00.00.0
Right-of-use (leased) assets0.30.60.91.20.70.00.10——
Other intangible assets00.00.00.00.00.10.10.10.10.1
Total assets6.37.48.2181911104.17.41.7
Accounts payable0.40.50.80.4r0.50.30.30.10.10.5
Current liabilities1.41.91.81.5r1.81.41.11.80.50.6
Lease liabilities (non-current)00.30.60.90.600.00——
Total liabilities1.42.22.52.4r2.41.41.11.81.31.1
Retained earnings−175−168−155−142r−130−120−112−106−99−94
Shareholders' equity4.95.15.815r17r9.49.42.46.10.7
Minority interests———0−0.1−0.1−0.1−0.1−0.1−0.1
Total equity——5.815r179.39.32.36.00.6
Total liabilities and equity6.37.48.2181911104.17.41.7
Shares outstanding0.3r0.2r0.3r2.3r1515r9.4r1.3r188.8
Cash-flow statement
Depreciation and amortization0.30.30.40.20.10.00.00.00.00.0
Share-based compensation0.30.41.21.10.80.80.81.31.32.2
Cash from operating activities−7.0−7.6−10−11−9.8−6.8−5.2−4.3−3.9−3.5
Capital expenditure−0.00−0.3−0.9−0.3−0.1−0.20−0.0−0.0
Cash from investing activities−0.00−0.3−0.9−0.3−0.1−0.20−0.0−0.0
Shares issued6.94.7r1.38.9——————
Cash from financing activities6.57.71.38.9177.1111.19.33.0
Exchange-rate effect on cash0.0−0.00.0−0.00—————
Change in cash−0.50.1−9.1−2.5r7.3—————
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Aethlon Medical, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2026
$827 K
James B. Frakes
Other top executives, average
$402 K
the CEO earned 2.1× this
$100 invested is now
$1
Aethlon Medical, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2026James B. Frakes$827 K$827 K$402 K$1
2025James B. Frakes$500 K$495 K$438 K$9
2024James B. Frakes$505 K$395 K$404 K$44

Source: SEC proxy statement (Form DEF 14A) · as of Mar 31, 2026

Events at Aethlon Medical, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Change in control 1 · Directors and officers 3 · Material agreement 5 · Shareholder rights changed 3 · Bylaws or fiscal year changed 4 · Shareholder vote 3 · Results announced 6

Aethlon Medical, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Bylaws or fiscal year changed8-K
Shareholder vote8-K/A
Directors and officersShareholder vote8-K
Change in controlMaterial agreement8-K
Directors and officers8-K
Results announced8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Material agreement8-K
Results announced8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Material agreement8-K
Material agreementShareholder rights changed8-K
Results announced8-K
Delisting notice8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Material agreement8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Aethlon Medical, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2025$2 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Jan 2020$3 MPrivate placement after listing$2 to $10 million7optionsSEC
Jun 2015$6 MPrivate placement after listing$2 to $10 million19equity, optionsSEC
Dec 2014$3 MPrivate placement after listing$2 to $10 million4equity, optionsSEC
Oct 2013$2 MPrivate placement after listingUnder $2 million22equity, optionsSEC
Jun 2012$2 MNo. 2$2 to $10 million27equity, optionsSEC
Nov 2011$1 MNo. 1Under $2 million10debt, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Aethlon Medical, Inc. compares in Medical Devices

  • Market cap$9 M · higher than 4% of 142
  • Revenue growth96.5% · higher than 95% of 104
  • Price / book1.8× · lower than 66% of 99
  • FCF yield-78.9% · higher than 7% of 76

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
Aethlon Medical, Inc.🇺🇸$9 M——+96.5%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending March-2026
Balance sheet:
As of March-2026
Employees:
As of June 8, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, Wikidata, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Aethlon Medical, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Aethlon Medical, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Aethlon Medical, Inc.? Suggest a correction